Please login to the form below
Norway
This page shows the latest Norway news and features for those working in and with pharma, biotech and healthcare.
CEPI says $2bn is needed for COVID-19 vaccine development
The German government’s Federal Ministry of Education and Research has already provided £157m to support CEPI’s development of a COVID-19 vaccine, joining the governments of Norway and the
Latest news
-
IQVIA and partners set up cancer ‘data hub’ to speed up research
The study showed that the UK performed worse than Australia, Canada, Denmark, Ireland, New Zealand and Norway in terms of cancer survival rates. .
-
New efficacy data boosts Aimovig’s migraine market lead
The data will be presented at the European Academy of Neurology's (EAN) annual meeting in Oslo, Norway.
-
Resurgent Diurnal raises £5.4m for twin product filings
In March, Diurnal also signed its first partnership for Alkindi with Swedish group Anthrop Pharmaceuticals, which covers the commercialisation of the drug in Sweden, Norway, Denmark, Finland and Iceland, a
-
Brexit "having impact on EU drug development”
states, plus Iceland and Norway.
-
UK business: Brexit deadlock causing “frustration and anger”
as Norway Plus – which was another EFTA/EEA approach.
More from news
Approximately 1 fully matching, plus 125 partially matching documents found.
Latest Intelligence
-
Developing a COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI), an Oslo, Norway-based nonprofit, is helping to coordinate the development of a COVID-19 vaccine and is leading the efforts to finance the
-
Will biosimilars ever catch on in the US?
Notably the biosimilar Renflexis (infliximab-abda) achieved a 70-80% price reduction to its reference product in both Norway and Denmark.
-
The case for a second Brexit referendum: “We need the informed consent of the people”
As many in the pharma industry know, the EEA allows Norway, Iceland and Liechtenstein to be part of the EMA and gain access to the new medicines at the same time.
-
The tipping point
National policy mandates to switch from the originator to biosimilars, as has been the case in Norway, have resulted in rapid and almost complete biosimilar market penetration.
-
Building a bright future
We have many examples where small molecule and biosimilars have improved uptake such as the case of infliximab in Norway, which was supported by the government that sponsored clinical trials showing
More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.
Latest appointments
-
Gilead Sciences appoints general manager, Canada
Brysting was most recently general manager of Gilead Nordics, comprising the company's businesses in Sweden, Norway, Denmark, Finland and Iceland.
-
Targovax appoints chief financial officer
Dr Wiklund joins the Oslo, Norway-based immuno-oncology specialist from Aker Biomarine Antarctic, where he served as director of product innovation.
-
Algeta execs join Targovax
Anna-Kirsti Aksnes and Tina Madsen join the firm. Norway's Targovax has added to its senior team with the appointment of two executives from Algeta.
-
Anker Lundemose appointed CEO of Bionor Pharma
The Norway-based biotech, which is focused on peptide-based vaccines for HIV, said Dr Lundemose will take over the role from March 1, when his predecessor Steen Krøyer becomes deputy
-
Matt Regan named AbbVie’s general manager in UK
Was formerly general manager of Abbott in Norway. AbbVie, the new independent biopharma spin-out from Abbott, has appointed Matt Regan as general manager of its UK business. ... Regan was formerly general manager for Abbott in Norway and will now oversee
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Imperial College London to lead major coronavirus home testing programme
- ViiV takes on Gilead’s PReP dominance with HIV injectable data
- Moderna’s coronavirus vaccine hits first objectives
- Roche says antibody test for COVID-19 should be ready in May
- AZ secures capacity for one billion coronavirus vaccine doses
- UK’s new COVID-19 trial initiative fast-tracks BerGenBio’s bemcentinib
- AZ secures capacity for one billion coronavirus vaccine doses
- EMA starts review of MorphoSys’ tafasitamab for lymphoma
- Gilead, Galapagos dip on mixed ulcerative colitis data
- Roche makes protein degradation play with $135m Vividion deal
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- UK government expands coronavirus testing criteria
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
- Ben Speller shares his thoughts on the value of disease specific congresses...
- OPEN Health use PR to support clinical trial recruitment
- International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
- Covid-19: what could it mean for the diabetic population?
- Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...
Quick links
Infographics
